Guiding treatment with resistance testing

The most recent guidelines issued by the British HIV Association (BHIVA), the EuroGuidelines Resistance Group, the US Department of Health and Human Services, and the IAS-USA all recommend the routine use of resistance testing in patient care. Genotypic testing is generally preferred in treatment-experienced patients on a first- or second-line regimen because it is widely available and relatively cost-effective. However, phenotypic testing can be more informative in patients with complex resistance patterns. See the Treatment guidelines section for more specifics on recommendations for resistance testing. 

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.